American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 647-656, November 2009

Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti–Vascular Endothelial Growth Factor Therapies

  • Karl Csaky

      Affiliations

    • Ophthalmic Unit, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationInquiries to Karl Csaky, Ophthalmic Unit, DCRI, Duke University Medical Center, Durham, NC 27710
    • ,
  • Diana V. Do

      Affiliations

    • The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland

Accepted 8 June 2009. published online 26 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0002-9394(09)00449-8

doi:10.1016/j.ajo.2009.06.014

American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 647-656, November 2009

Article Tools

* Image Usage & Resolution